Results 211 to 220 of about 178,517 (322)

Supplementary Figure S1 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

, 2023
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei, Jun Zhu   +19 more
openalex   +2 more sources

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience. [PDF]

Hemasphere
Innocenti I, Mosca A, Tomasso A, Galitzia A, Scarfò L, Morelli F, Galli E, Martini F, Sangiorgi E, Laureana R, Benintende G, Mattiello V, Chiriu S, Del Principe MI, Zamprogna G, Gentile M, Martino EA, Cappello E, Montalbano MC, Farina G, Innao V, Stirparo L, Patti C, Sportoletti P, Fresa A, Catania G, Coscia M, Bellesi S, Tedeschi A, Sanna A, Visentin A, Autore F, Pasquale R, Trentin L, Varettoni M, Ghia P, Murru R, Laurenti L.   +37 more
europepmc   +1 more source

The BMX Tyrosine Kinase : A Signal Mediator in Hematopoietic and Endothelial/Epithelial Cells [PDF]

, 2003
Ekman, Niklas
core  

Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema. [PDF]

JAAD Case Rep
Meledathu S, Chu P, Feldman T, Goy AH, Rosenstein RK.   +4 more
europepmc   +1 more source

Susceptibility to Cryptococcus neoformans Infection with Bruton's Tyrosine Kinase Inhibition. [PDF]

Infect Immun, 2023
Messina JA, Giamberardino CD, Tenor JL, Toffaletti DL, Schell WA, Asfaw YG, Palmucci JR, Lionakis MS, Perfect JR.   +8 more
europepmc   +1 more source

P3612Potential for Bruton's tyrosine kinase inhibitors as additional antiplatelet agents in acute coronary syndromes [PDF]

, 2018
Maria Bhatti, Olga Michail, Sarah L Ayton, N.D. Gollop, Alisdair Ryding, Stuart A. Rushworth, Kristian M. Bowles, Marcus Flather   +7 more
openalex   +1 more source

RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells. [PDF]

J Transl Int Med
Dong XD, Lu Q, Li YD, Cai CY, Teng QX, Lei ZN, Wei ZH, Yin F, Zeng L, Chen ZS.   +9 more
europepmc   +1 more source

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects [PDF]

, 2019
Song Mu, Zhiyu Tang, William Novotny, Manal Tawashi, Ta‐Kai Li, Ying Ou, Srikumar Sahasranaman   +6 more
openalex   +1 more source

Correction: Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. [PDF]

J Exp Clin Cancer Res
Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, Guo X, Zhao P.   +7 more
europepmc   +1 more source

Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations

, 2021
Angus Voice, Gary Tresadern, Rebecca M. Twidale, Herman van Vlijmen, Adrian J. Mulholland   +4 more
openalex   +2 more sources